Cookie Consent by PrivacyPolicies.com

Publicaciones científicas

93 Publicaciones científicas disponibles

  • Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors

    11 de mayo de 2020 | Revista: Nature Medicine

    Schalper KA (1), Carleton M (2), Zhou M (3), Chen T (3), Feng Y (3), Huang SP (3), Walsh AM (4), Baxi V (4), Pandya D (5), Baradet T (2), Locke D (2), Wu Q (5), Reilly TP (5), Phillips P (2), Nagineni V (6), Gianino N (6), Gu J (7), Zhao H (7), Perez-Gracia JL (8,9), Sanmamed MF (8,9,10,11), Melero I (12,13,14).

    (1) Department of Pathology, Yale University School of Medicine, New Haven, CT, USA. kurt.schalper@yale.edu.
    (2) Department of Translational Medicine, Bristol-Myers Squibb, Princeton, NJ, USA.
    (3) Department of Global Biometric Sciences, Bristol-Myers Squibb, Princeton, NJ, USA.
    (4) Department of Translational Bioinformatics, Bristol-Myers Squibb, Princeton, NJ, USA.
    (5) Department of Research and Early Development, Bristol-Myers Squibb, Princeton, NJ, USA.
    (6) Department of Pathology, Yale University School of Medicine, New Haven, CT, USA.
    (7) Department of Biostatistics, School of Public Health, Yale University, New Haven, CT, USA.
    (8) Oncology Department, Clinica Universidad de Navarra, Pamplona, Spain.
    (9) Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
    (10) Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.
    (11) Department of Immunology and Immunotherapy, Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.
    (12) Oncology Department, Clinica Universidad de Navarra, Pamplona, Spain.
    (13) Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
    (14) Department of Immunology and Immunotherapy, Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.


  • Prognostic value of macrophage polarization markers in epithelial neoplasms and melanoma

    14 de abril de 2020 | Revista: Modern Pathology

    López-Janeiro Á (1), Padilla-Ansala C (2), de Andrea CE (3,4,5,6), Hardisson D (2,7,8), Melero I (5,6,9,10).

    (1) Department of Pathology, Hospital Universitario La Paz-IdiPaz, Madrid, Spain.
    (2) Department of Pathology, Hospital Universitario La Paz-IdiPaz, Madrid, Spain.
    (3) Department of Pathology, Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain.
    (4) Department of Anatomy, Physiology and Pathology, University of Navarra, Pamplona, Spain.
    (5) Navarra Institute for Health Research (IDISNA), Pamplona, Spain.
    (6) Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
    (7) Molecular Pathology and Therapeutic Targets Group, La Paz University Hospital-IdiPaz, Madrid, Spain.
    (8) Faculty of Medicine, Universidad Autónoma de Madrid, Madrid, Spain.
    (9) Department of Immunology and Immunotherapy, Clínica Universidad de Navarra, Pamplona, Spain.
    (10) Program of Immunology and Immunotherapy, CIMA Universidad de Navarra, Pamplona, Spain.


  • CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity

    6 de abril de 2020 | Revista: Immunity

    Teijeira Á (1), Garasa S (2), Gato M (3), Alfaro C (4), Migueliz I (2), Cirella A (2), de Andrea C (5), Ochoa MC (6), Otano I (3), Etxeberria I (3), Andueza MP (7), Nieto CP (2), Resano L (7), Azpilikueta A (4), Allegretti M (8), de Pizzol M (8), Ponz-Sarvisé M (9), Rouzaut A 6, Sanmamed MF 6, Schalper K 10, Carleton M (11), Mellado M (12), Rodriguez-Ruiz ME ()6, Berraondo  P (6), Perez-Gracia JL (7), Melero I (13).

    (1) Program for Immunology and Immunotherapy Department, CIMA, Universidad de Navarra, 31008 Pamplona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Navarra Institute for Health Research (IDISNA), 31008 Pamplona, Spain.
    (2) Program for Immunology and Immunotherapy Department, CIMA, Universidad de Navarra, 31008 Pamplona, Spain.
    (3) Program for Immunology and Immunotherapy Department, CIMA, Universidad de Navarra, 31008 Pamplona, Spain; Navarra Institute for Health Research (IDISNA), 31008 Pamplona, Spain.
    (4 Program for Immunology and Immunotherapy Department, CIMA, Universidad de Navarra, 31008 Pamplona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
    (5) Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Navarra Institute for Health Research (IDISNA), 31008 Pamplona, Spain; Department of Oncology, Clinica Universidad de Navarra, 31008 Pamplona, Spain.
    (6) Program for Immunology and Immunotherapy Department, CIMA, Universidad de Navarra, 31008 Pamplona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Navarra Institute for Health Research (IDISNA), 31008 Pamplona, Spain.
    (7) Department of Oncology, Clinica Universidad de Navarra, 31008 Pamplona, Spain.
    (8) Dompé Farmaceutici S.p.A., 20122 Milano, Italy.
    (9) Navarra Institute for Health Research (IDISNA), 31008 Pamplona, Spain; Department of Oncology, Clinica Universidad de Navarra, 31008 Pamplona, Spain.
    (10) Department of Pathology, Yale University School of Medicine, New Haven, CT 06520, USA.
    (11) Bristol Myers Squibb, Lawrence Township, NJ 08648, USA.
    (12) Chemokine Signaling Group, Department of Immunology and Oncology, Centro Nacional de Biotecnología (CNB-CSIC), 28049 Madrid, Spain.
    (13) Program for Immunology and Immunotherapy Department, CIMA, Universidad de Navarra, 31008 Pamplona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Navarra Institute for Health Research (IDISNA), 31008 Pamplona, Spain.


  • Human CD8 T cells are susceptible to TNF-mediated activation-induced cell death

    15 de marzo de 2020 | Revista: Theranostics

    Otano I (1,2), Alvarez M (1,2), Minute L (1,2), Ochoa MC (1,2,3,4), Migueliz I (2,4), Molina C (1,2), Azpilikueta A (1,2), de Andrea CE (2,3,5,6), Etxeberria I (1,2), Sanmamed MF (1,2,7), Teijeira Á (1,2,3), Berraondo P (1,2,3), Melero I (1,2,3,7,4).

    (1) Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.
    (2) Navarra Institute for Health Research (IDISNA), Pamplona, Spain.
    (3) Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
    (4) Department of Immunology and Immunotherapy, Clínica Universidad de Navarra, Pamplona, Spain.
    (5) Department of Pathology, Clínica Universidad de Navarra, Pamplona, Spain.
    (6) Department of Histology and Pathology, Universidad de Navarra, Pamplona, Spain.
    (7) Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain.

No hay más publicaciones científicas

No hay más páginas para cargar